{"entity":{"type":"insider","cik":"0001353528","url":"/insider/0001353528","json_url":"/insider/0001353528.json","name":"Cassella James V","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":18,"n_filings":14,"first":"2009-12-18","last":"2023-02-16","span_basis":"filed_date"},"name_variants":[{"name":"Cassella James V","source":"filing","n_filings":14,"first_seen":"2009-12-18","last_seen":"2023-02-16"}],"transactions":[{"id":7830488,"accession":"0001209191-23-009949","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-009949","line_url":"/filing/0001209191-23-009949#line-1","is_derivative":false,"issuer_cik":"0001353528","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353528","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3762.0,"shares_display":"3,762","price_per_share":8.34,"price_display":"8.34","price_state":"stated","total_value":31375.08,"total_display":"31,375.08","shares_owned_after":173061.0,"shares_owned_after_display":"173,061","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-15","filed_date":"2023-02-16","scope":"insider"},{"id":7867472,"accession":"0001209191-23-005620","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-005620","line_url":"/filing/0001209191-23-005620#line-1","is_derivative":false,"issuer_cik":"0001353528","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353528","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10106.0,"shares_display":"10,106","price_per_share":8.35,"price_display":"8.35","price_state":"stated","total_value":84385.1,"total_display":"84,385.10","shares_owned_after":176823.0,"shares_owned_after_display":"176,823","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-30","filed_date":"2023-01-31","scope":"insider"},{"id":7966782,"accession":"0001209191-23-002551","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-002551","line_url":"/filing/0001209191-23-002551#line-1","is_derivative":false,"issuer_cik":"0001353528","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353528","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2893.0,"shares_display":"2,893","price_per_share":7.25,"price_display":"7.25","price_state":"stated","total_value":20974.25,"total_display":"20,974.25","shares_owned_after":186929.0,"shares_owned_after_display":"186,929","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-06","filed_date":"2023-01-09","scope":"insider"},{"id":6844803,"accession":"0001209191-22-010072","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-010072","line_url":"/filing/0001209191-22-010072#line-1","is_derivative":false,"issuer_cik":"0001353528","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353528","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3762.0,"shares_display":"3,762","price_per_share":3.09,"price_display":"3.09","price_state":"stated","total_value":11624.58,"total_display":"11,624.58","shares_owned_after":189822.0,"shares_owned_after_display":"189,822","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-14","filed_date":"2022-02-16","scope":"insider"},{"id":6294266,"accession":"0001209191-22-002401","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-002401","line_url":"/filing/0001209191-22-002401#line-1","is_derivative":false,"issuer_cik":"0001353528","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353528","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2894.0,"shares_display":"2,894","price_per_share":3.19,"price_display":"3.19","price_state":"stated","total_value":9231.86,"total_display":"9,231.86","shares_owned_after":83084.0,"shares_owned_after_display":"83,084","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-05","filed_date":"2022-01-07","scope":"insider"},{"id":5201668,"accession":"0001209191-21-051819","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-051819","line_url":"/filing/0001209191-21-051819#line-1","is_derivative":false,"issuer_cik":"0001353528","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353528","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8086.0,"shares_display":"8,086","price_per_share":3.28,"price_display":"3.28","price_state":"stated","total_value":26522.08,"total_display":"26,522.08","shares_owned_after":85978.0,"shares_owned_after_display":"85,978","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-16","filed_date":"2021-08-17","scope":"insider"},{"id":5244053,"accession":"0001209191-21-011614","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-011614","line_url":"/filing/0001209191-21-011614#line-1","is_derivative":false,"issuer_cik":"0001353528","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353528","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3763.0,"shares_display":"3,763","price_per_share":7.32,"price_display":"7.32","price_state":"stated","total_value":27545.16,"total_display":"27,545.16","shares_owned_after":94064.0,"shares_owned_after_display":"94,064","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-16","filed_date":"2021-02-17","scope":"insider"},{"id":2471986,"accession":"0001209191-20-047577","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-047577","line_url":"/filing/0001209191-20-047577#line-1","is_derivative":false,"issuer_cik":"0001353528","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353528","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4354.0,"shares_display":"4,354","price_per_share":10.37,"price_display":"10.37","price_state":"stated","total_value":45150.98,"total_display":"45,150.98","shares_owned_after":76127.0,"shares_owned_after_display":"76,127","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-17","filed_date":"2020-08-19","scope":"insider"},{"id":5961164,"accession":"0001209191-18-025549","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-025549","line_url":"/filing/0001209191-18-025549#line-1","is_derivative":false,"issuer_cik":"0001353528","issuer_name":"CONCERT PHARMACEUTICALS, INC.","issuer_ticker":"CNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353528","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10582.0,"shares_display":"10,582","price_per_share":20.1767,"price_display":"20.18","price_state":"stated","total_value":213509.8394,"total_display":"213,509.84","shares_owned_after":30000.0,"shares_owned_after_display":"30,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-04-17","filed_date":"2018-04-19","scope":"insider"},{"id":2967503,"accession":"0001209191-12-059482","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-059482","line_url":"/filing/0001209191-12-059482#line-1","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (EVP, R&D and CSO)","officer_title":"EVP, R&D and CSO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4558.0,"shares_display":"4,558","price_per_share":4.8959,"price_display":"4.90","price_state":"stated","total_value":22315.5122,"total_display":"22,315.51","shares_owned_after":950.0,"shares_owned_after_display":"950","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-12-26","filed_date":"2012-12-27","scope":"insider"},{"id":3536346,"accession":"0001209191-12-043662","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-043662","line_url":"/filing/0001209191-12-043662#line-1","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (EVP, R&D and CSO)","officer_title":"EVP, R&D and CSO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":4.1364,"price_display":"4.14","price_state":"stated","total_value":41364.0,"total_display":"41,364.00","shares_owned_after":5508.0,"shares_owned_after_display":"5,508","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-08-27","filed_date":"2012-08-29","scope":"insider"},{"id":3381908,"accession":"0001209191-12-033063","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-12-033063","line_url":"/filing/0001209191-12-033063#line-1","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (SVP, Research & Development)","officer_title":"SVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":46222.0,"shares_display":"46,222","price_per_share":0.3381,"price_display":"0.34","price_state":"stated","total_value":15627.6582,"total_display":"15,627.66","shares_owned_after":157801.0,"shares_owned_after_display":"157,801","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-06-06","filed_date":"2012-06-08","scope":"insider"},{"id":9266914,"accession":"0001209191-09-058158","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-09-058158","line_url":"/filing/0001209191-09-058158#line-3","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (SVP, Research & Development)","officer_title":"SVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12405.0,"shares_display":"12,405","price_per_share":2.1269,"price_display":"2.13","price_state":"stated","total_value":26384.1945,"total_display":"26,384.19","shares_owned_after":12219.0,"shares_owned_after_display":"12,219","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-18","filed_date":"2009-12-21","scope":"insider"},{"id":5816701,"accession":"0001209191-09-058002","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-09-058002","line_url":"/filing/0001209191-09-058002#line-3","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (SVP, Research & Development)","officer_title":"SVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12408.0,"shares_display":"12,408","price_per_share":2.1269,"price_display":"2.13","price_state":"stated","total_value":26390.5752,"total_display":"26,390.58","shares_owned_after":12214.0,"shares_owned_after_display":"12,214","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-18","filed_date":"2009-12-18","scope":"insider"},{"id":9266913,"accession":"0001209191-09-058158","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-058158","line_url":"/filing/0001209191-09-058158#line-2","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (SVP, Research & Development)","officer_title":"SVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4283.0,"shares_display":"4,283","price_per_share":2.2007,"price_display":"2.20","price_state":"stated","total_value":9425.5981,"total_display":"9,425.60","shares_owned_after":24624.0,"shares_owned_after_display":"24,624","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-17","filed_date":"2009-12-21","scope":"insider"},{"id":5816698,"accession":"0001209191-09-058002","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-09-058002","line_url":"/filing/0001209191-09-058002#line-2","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (SVP, Research & Development)","officer_title":"SVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4284.0,"shares_display":"4,284","price_per_share":2.2007,"price_display":"2.20","price_state":"stated","total_value":9427.7988,"total_display":"9,427.80","shares_owned_after":24622.0,"shares_owned_after_display":"24,622","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-17","filed_date":"2009-12-18","scope":"insider"},{"id":9266915,"accession":"0001209191-09-058158","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-058158","line_url":"/filing/0001209191-09-058158#line-1","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (SVP, Research & Development)","officer_title":"SVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7731.0,"shares_display":"7,731","price_per_share":2.4071,"price_display":"2.41","price_state":"stated","total_value":18609.2901,"total_display":"18,609.29","shares_owned_after":28907.0,"shares_owned_after_display":"28,907","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-16","filed_date":"2009-12-21","scope":"insider"},{"id":5816696,"accession":"0001209191-09-058002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-09-058002","line_url":"/filing/0001209191-09-058002#line-1","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":"0001353528","owner_name":"Cassella James V","owner_url":"/insider/0001353528","role":"Officer (SVP, Research & Development)","officer_title":"SVP, Research & Development","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7732.0,"shares_display":"7,732","price_per_share":2.4071,"price_display":"2.41","price_state":"stated","total_value":18611.6972,"total_display":"18,611.70","shares_owned_after":28906.0,"shares_owned_after_display":"28,906","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-16","filed_date":"2009-12-18","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":18,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":18,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":18},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001367920","name":"CONCERT PHARMACEUTICALS, INC.","url":"/issuer/0001367920","role":"Officer (Chief Development Officer)","n_filings":9,"first_seen":"2018-04-19","last_seen":"2023-02-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001344413","name":"Alexza Pharmaceuticals Inc.","url":"/issuer/0001344413","role":"Officer (EVP, R&D and CSO)","n_filings":5,"first_seen":"2009-12-18","last_seen":"2012-12-27"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001353528","retrieved_at":"2026-08-22T03:27:51+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}